Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-associated chromosomal translocations and are key regulators of cell growth. Therefore, efforts to generate inhibitors of CBP/p300 are of clinical value. We developed a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, I-CBP112, that targets the CBP/p300 bromodomains. Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity. I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin. Collectively, we report the development and preclinical evaluation of a novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells. The synergistic effects of I-CBP112 and current standard therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.

[1]  L. Wodicka,et al.  Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology , 2014 .

[2]  Jessica E. Bolden,et al.  Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition , 2014, Cell reports.

[3]  A. Gingras,et al.  Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching , 2014, Epigenetics & Chromatin.

[4]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[5]  Zhoulei Li,et al.  BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma , 2014, Proceedings of the National Academy of Sciences.

[6]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[7]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[8]  S. Kaufmann,et al.  Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  E. Ortega,et al.  Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation , 2013, Nature Structural &Molecular Biology.

[10]  S. Knapp,et al.  PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.

[11]  Li-li Wang,et al.  A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells , 2013, PloS one.

[12]  K. Cermakova,et al.  Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75) , 2013, Leukemia.

[13]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[14]  S. Knapp,et al.  Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family , 2012, Bioorganic & medicinal chemistry.

[15]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[16]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[17]  B. Göttgens,et al.  The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells , 2011, Molecular and Cellular Biology.

[18]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[19]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[20]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[21]  A. Melnick,et al.  The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation , 2011, Science.

[22]  Jihong Chen,et al.  Life and death of transcriptional co-activator p300 , 2011, Epigenetics.

[23]  W. Parson,et al.  Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines , 2011, Molecular Cancer Therapeutics.

[24]  Ming-Ming Zhou,et al.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.

[25]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[26]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[27]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[28]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[29]  Tina N. Davis,et al.  Systematic in vivo structure-function analysis of p300 in hematopoiesis. , 2009, Blood.

[30]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[31]  S. Agrawal,et al.  Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. , 2009, Journal of medicinal chemistry.

[32]  A. Brasier,et al.  The STAT3 NH2-terminal Domain Stabilizes Enhanceosome Assembly by Interacting with the p300 Bromodomain* , 2008, Journal of Biological Chemistry.

[33]  I. Kitabayashi,et al.  Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis , 2008, Cancer science.

[34]  Zhenghe Wang,et al.  Differential binding modes of the bromodomains of CREB-binding protein (CBP) and p300 with acetylated MyoD. , 2008, Biochemical and biophysical research communications.

[35]  J. Rehg,et al.  Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. , 2006, Blood.

[36]  Wei-Guo Zhu,et al.  Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1 , 2006, Molecular and Cellular Biology.

[37]  T. Golub,et al.  Conditional MLL‐CBP targets GMP and models therapy‐related myeloproliferative disease , 2005, The EMBO journal.

[38]  J. Rowley,et al.  Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16) , 2004, Genes, chromosomes & cancer.

[39]  C. Caldas,et al.  p300/CBP and cancer , 2004, Oncogene.

[40]  W. Taylor,et al.  Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. , 2004, Cancer cell.

[41]  Roberto Sanchez,et al.  Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.

[42]  J. Tschopp,et al.  BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.

[43]  Changchun Du,et al.  Chromatin‐related properties of CBP fused to MLL generate a myelodysplastic‐like syndrome that evolves into myeloid leukemia , 2000, The EMBO journal.

[44]  D. Livingston,et al.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.

[45]  M. Cleary,et al.  CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity , 1999, Molecular and Cellular Biology.

[46]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[47]  F. Behm,et al.  All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. , 1997, Blood.

[48]  Diwakar,et al.  SUPPLEMENTARY INFORMATION for Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes , 2014 .

[49]  L. Cooper,et al.  Mammalian two-hybrid assays for studies of interaction of p300 with transcription factors. , 2013, Methods in molecular biology.

[50]  Stefan Knapp,et al.  Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.